the United States and Canada have implemented policies mandating the fortification of cereal grain flour products with folic acid (0.4 to 1.4 mg/lb) to reduce the risk of neural tube birth defects in newborns. 1 The disadvantage of this measure for researchers is that randomized, controlled trials of total homocysteine (tHcy)-lowering therapy, by means of folic acid and other multivitamin therapies, to prevent cardiovascular outcomes in the US and Canada are likely to achieve only Ϸ20% to 25% of the initially projected mean treatment effects of tHcy-lowering therapy (1.0 to 2.0 mol/L versus 4.0 to 6.0 mol/L). 2,3 Indeed, the recently completed Vitamins In Stroke Prevention (VISP) Study, which compared high-dose multivitamins (including folic acid 2.5 mg, vitamin B 12 0.4 mg, and vitamin B 6 25 mg) with low-dose multivitamins (including folic acid 0.02 mg, vitamin B 12 0.006 mg, vitamin B 6 0.2 mg) in 3,680 stroke survivors, only achieved a mean 2.0 mol/L reduction in tHcy. 4, 5 The results failed to reliably exclude a modest but clinically important effect of folic acid-based multivitamin therapy in reducing the risk of major vascular events and death by up to 20% and 30%, respectively. 5 The VITAmins TO Prevent Stroke (VITATOPS) Trial is the only large randomized, double-blind, placebo-controlled trial currently testing the "homocysteine hypothesis" in patients with previous transient ischemic attack (TIA) or stroke. 6, 7 It is being conducted in 19 countries, most where mandatory folic acid fortification of cereal grain products is not implemented. Patients are randomized to once daily treatment with placebo or the combination of folic acid 2.0 mg plus vitamin B 12 0.5 mg plus vitamin B6 25 mg. The projected average treatment effect is a 4.0 mol/L reduction in tHcy. 7 We examined the effect of the active VITATOPS trial medication on mean tHcy concentrations at 6 months after randomization, compared with placebo, among 285 consecutive patients with recent stroke or TIA randomized in one center in Perth, Australia. Fasting plasma tHcy was measured at baseline and at 6 months after randomisation using high-performance liquid chromatography (HPLC). The significance of any difference in plasma tHcy between multivitamin-and placebo-treated patients was examined using an independent t test. For the purposes of this analysis, only a third-party statistician (Q.Y.) not involved in any aspects of the design or day-to-day running of the trial was unblinded to treatment allocation.
in many other countries participating in the VITATOPS trial (eg, Hong Kong, India, Malaysia, Moldova, Pakistan, Philippines, Singapore, Sri Lanka) where nutritional status is likely to be lower and any effect of supplementation is also likely to be lower or nonexistent.
However, our estimate of the effect of multivitamins on plasma tHcy is unlikely to be exaggerated by survival bias or loss to follow-up because a similar number died or declined repeat blood testing from each treatment group and baseline characteristics of these patients were similar to those of patients who underwent repeat blood collection at 6 months (data not presented). Furthermore, the observed treatment effect is likely to underestimate the true effect size because 9.1% of patients allocated active VITATOPS treatment ceased taking their VITATOPS tablets during the 6-month follow-up period, and some who were allocated placebo took up folic acid therapy. Ͻ0.0001 *The difference between the two treatment groups in tHcy at 6 months after randomisation is 12.8Ϫ9.1 mol/Lϭ 3.7 mol/L, 95% confidence interval: 2.7 to 4.7 mol/L (PϽ0.0001).
Fasting Plasma tHcy Levels at Baseline and 6 Months
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